A phase 1 study of a novel glycosylated Fc-fused glucagon-like peptide-1 receptor agonist suggests it could deliver similar blood glucose-lowering efficacy but with fewer gastrointestinal side effects relative to existing medications in the class.
Glucose-lowering drugs or strategies reduce the risk for major adverse cardiovascular events and death in people with or at risk for type 2 diabetes, but their impact on heart failure may depend on weight loss, shows an updated systematic review and meta-analysis.
People with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists have a lower risk for serious renal adverse events than those given dipeptidyl peptidase-4 inhibitors, indicate results from a Scandinavian real-world study.
Combining a glucagon-like peptide-1 receptor agonist with an experimental compound could increase the function and numbers of beta cells, suggest preclinical findings in Science Translational Medicine.
An umbrella review of meta-analyses has demonstrated mixed associations between different glucose-lowering agents and cardiovascular outcomes in people with type 2 diabetes, with the results favoring sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists as cardioprotective agents.
The failure of intensive medication to halt beta-cell decline in children with early type 2 diabetes occurs despite them having better baseline beta-cell and alpha-cell function than newly diagnosed adults, say the RISE researchers.
Findings from the NewLira trial suggest that addition of the glucagon-like peptide-1 receptor agonist liraglutide to insulin treatment may preserve postprandial insulin secretion among adults with newly diagnosed type 1 diabetes.
Treatment with the glucagon-like peptide-1 receptor agonist semaglutide results in better glycemic control than the sodium-glucose cotransporter 2 inhibitor canagliflozin among people with type 2 diabetes uncontrolled on metformin, indicate the SUSTAIN 8 trial results.
Researchers at the 55th EASD Annual Meeting in Barcelona, Spain, have presented primary data and subanalyses from a number of the PIONEER trials investigating the efficacy of oral semaglutide in people with type 2 diabetes.
Patients initiating a flexible combination of basal insulin plus a glucagon-like peptide-1 receptor agonist have similar improvements in glycemic control to those initiating a fixed combination, but with greater weight loss, real-world study data show.
Second-line therapy choices for people with type 2 diabetes vary widely throughout the world and are influenced not only by clinical characteristics but also non-medical factors such as affordability and availability, results from the DISCOVER study show.
The PIONEER 6 trial demonstrates the noninferior cardiovascular safety profile of oral semaglutide compared with placebo, but fails to demonstrate superiority, despite an overall positive trend and significance for cardiovascular death.
The glucagon-like peptide-1 receptor agonist dulaglutide has demonstrated significant cardioprotection in the REWIND trial, despite the trial population being lower risk than usual for cardiovascular outcome trials.
Intensive antidiabetic treatment in adults with newly diagnosed type 2 diabetes slows the decline in beta-cell function, but this is not sustained after the treatment is stopped, show the results of the RISE adult medication study.